Once laud­ed for its clin­i­cal suc­cess, Roche casts off car­dio pro­gram in­clacum­ab for a mere $2M to Glob­al Blood Ther­a­peu­tics

Five years ago, Roche tout­ed a clin­i­cal suc­cess for one of its mid-stage car­dio pro­grams, re­port­ing the in­ves­ti­ga­tion­al med showed promise in re­duc­ing heart dam­age. Promis­ing, they said, but ap­par­ent­ly not promis­ing enough. Roche qui­et­ly dis­con­tin­ued that pro­gram af­ter Phase II tri­als and we didn’t hear about it again un­til to­day: Roche has sold it to a San Fran­cis­co biotech for a pal­try $2 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.